You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《信而有證》中生製藥、美圖績後受壓 零跑汽車破頂後回吐 好友積極博反彈
恆指連跌3日後,早段反覆,高開64點後曾倒跌近百點,低見25,083點,之後又再靠穩,但早段高低波幅較窄,升幅不過100點。 恆指上日反覆回軟,資金偏向造淡。根據手機應用程式「信搜牛熊」數據,恆指好倉上日近2千萬離場,淡倉則有逾2千萬入場。 牛熊證街貨比例回落至約69:31,牛證重貨區兩萬五水平有資金加倉,相對期指張數增至逾1,700張;熊證部署則較爲分散,重貨區仍在較遠的25,800點水平。 牛熊證街貨分佈圖:https://www.citicswarrants.com/tc/cbbc/os-map 即市資金流方面,大市波幅有限,早段資金與上日情況相若,以換馬至貼價證爲主。 信證熱門牛熊證:恆指牛證(65435),收回價24,800點;恆指熊證(66851),收回價25,520點。 上日收市後公佈業績的股份跌多升少,包括中生製藥(01177)、美圖(01357)及零跑汽車(09863)等。 中生製藥中期多賺12%至近33.9億元人民幣,中期息每股派5仙,按年急升逾66%,股價早段向下,最多跌逾半成,下試10天線約7.58元的位置。 若預期股價在現水平或20天線(約7.38元)有支持,可以留意中藥認購證(19019),行使價8.08元,明年10月底到期,實際槓桿約2.7倍,由於條款相對貼價及長年期,短線部署博反彈或中長線看好走勢亦適合。 美圖方面,中期多賺逾三成,至3.9億元人民幣,與早前公佈的盈喜符合,首次派中期息4.5仙,早段股價反覆向下,升逾2%後曾倒跌近半成,試穿10元關。 繼續看好美圖走勢,可以留意美圖認購證(17945),行使價13.88元,明年1月到期,實際槓桿約3.4倍。 零跑汽車中期由虧轉盈,賺逾3,300萬人民幣,去年同期則蝕逾22億元人民幣,不派中期息,股價先升後回,早段曾再創上市新高,高見68.8元,之後曾於高位回吐逾4%。 跟進好倉,可留意零跑認購證(17011),行使價98.63元,明年7月底到期,實際槓桿約兩倍。 是日業績焦點: 小米(01810)認購證(14462),行使價63.88元,明年1 月底到期,實際槓桿約6.5倍 小米(01810)認沽證(14798),行使價46.45元,明年6月到期,實際槓桿約3.6倍 藥明(02269)認購證(18519),行使價48.48元,明年1月底到期,實際槓桿約4.4倍 舜宇(02382)認購證(18317),行使價100.038元,年底到期,實際槓桿約5.6倍 舜宇(02382)認沽證(14741),行使價73.82元,11月底到期,實際槓桿約4.6倍 更多窩輪產品及資訊:中信證券輪證網站:https://www.citicswarrants.com/tc/index 中信證券輪證頻道:https://www.citicswarrants.com/tc/education/video-channel 風險披露及免責聲明 本結構性產品並無抵押品,如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。 本資料由中信證券經紀(香港)有限公司 (「本行」或「發行人」) 編制,其僱員可能持有不時在本資料所述證券之權益 。結構性產品屬複雜產品,投資前閣下應詳閱有關上市文件,完全瞭解其性質及潛在風險,自行評估箇中風險,並於需要時尋求專業意見。以上資料僅供參考,並不構成購買或出售結構性產品或達成任何交易的要約、遊說、邀請、意見或建議,亦不構成投資意見或服務。結構性產品的價格可急跌或急升,投資者或會損失所有投資。牛熊證設有強制收回機制,因此有可能提早終止,在此情況下(i)N類牛熊證投資者會損失於牛熊證的全部投資;而(ii)R類牛熊證之剩餘價值則可能爲零。過往表現並非未來表現的指標。本行可能是結構性產品的唯一市場參與者,而結構性產品的二級市場可能有限。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account